Willkommen, schön sind Sie da!
Logo Ex Libris

Cancer Prevention II

  • Kartonierter Einband
  • 272 Seiten
(0) Erste Bewertung abgeben
Alle Bewertungen ansehen
More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day... Weiterlesen
237.00 CHF 189.60
Sie sparen CHF 47.40
Print on Demand - Auslieferung erfolgt in der Regel innert 4 bis 6 Wochen.
Bestellung & Lieferung in eine Filiale möglich


More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on Primary Therapy of Early Breast Cancer as well as Supportive Care in Cancer for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today's medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerlandand we fear in many other parts of the globesome 97%98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for curing and caring for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population.


This Recent Results in Cancer Research volume contains the majority of the invited expert contributions of the Fifth International Conference on Cancer Prevention, held 6-8 March 2008 at the University of St. Gallen, Switzerland. Written by some of the world's leading experts in the field, the volume constitutes a comprehensive update on the most important and recent developments in molecular biology and cancer genetics, regarding chiefly the upsurging, but still controversial, field of primary prevention, especially chemoprevention. This conference primarily addressed the four leading and most frequent solid tumor types - breast, colon, gynecological, and lung cancer - all of which demonstrate how such an approach is currently possible and important in clinical cancer prevention research. The future prospects of chemoprevention and the process of selecting the most successful target populations at risk are discussed.

Cancer Prevention and Health Politics. Do we make optimal use of the potential of cancer prevention? Predictors of successful cancer prevention programs. Cancer prevention in the developing world: mission impossible?Is cancer prevention ever going to be profitable?.- Cancer Prevention: The Scientific-Epidemiological Base. Energy metabolism, cancer risk, and cancer prevention. Promises and limitations of biomarkers.- Cancer Prevention, Tobacco and Nutrition. The EPIC study: an update. Anti-angiogenic properties of chemopreventive drugs: Fenretinide as a prototype. Retinoids and breast cancer prevention.- Cancer Prevention, Genetics and Vaccines. Cancer prevention by vaccination against hepatitis B.- Cancer Prevention and Target Organs I: Breast Cancer. Energy restriction for breast cancer prevention. The use of Tamoxifen and Raloxifene for the prevention of breast cancer. Prevention of ER-negative breast cancer. Exogenous and endogenous hormones, mammographic density and breast cancer risk can mammographic density be considered an intermediate marker of risk?.- Cancer Prevention and Target Organs II: Cancer of the Digestive Tract. Chemoprevention of oesophageal cancer and the AspECT trial.- Cancer Prevention and Target Organs III: Prostate Cancer. Review of diagnostic markers for prostate cancer. Selenium and vitamin E cancer prevention trial (SELECT): a nutrient approach to prostate cancer prevention. Prostate cancer prevention by short-term anti-androgens: the rationale behind design of pilot studies.- Cancer Prevention: Metabolic Aspects. Anti-angiogenic activity of a novel class of chemopreventive compounds: oleanic acid terpenoids.- Aspirin and NSAIDs in Cancer Prevention: Attempts at an International Consensus. Pharmacologic effects of NSAIDs and implications for the risks and benefits of long-term prophylactic use of asprin to prevent cancer. Aspirin and NSAIDs for the prevention of colorectal cancer. Aspirin and cancer risk: a summary review.


Titel: Cancer Prevention II
EAN: 9783642088810
ISBN: 3642088813
Format: Kartonierter Einband
Herausgeber: Springer Berlin Heidelberg
Genre: Medizin
Anzahl Seiten: 272
Gewicht: 417g
Größe: H235mm x B155mm x T14mm
Jahr: 2010
Untertitel: Englisch
Auflage: Softcover reprint of hardcover 1st ed. 2009

Weitere Produkte aus der Reihe "Recent Results in Cancer Research"